002755 Stock Overview Beijing Aosaikang Pharmaceutical Co., Ltd. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add noteBeijing Aosaikang Pharmaceutical Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Beijing Aosaikang Pharmaceutical Historical stock prices Current Share Price CN¥13.79 52 Week High CN¥15.10 52 Week Low CN¥6.50 Beta 0.33 1 Month Change 7.65% 3 Month Change 3.76% 1 Year Change 49.40% 3 Year Change 24.80% 5 Year Change -8.49% Change since IPO 19.50%
Recent News & Updates Innovent Biologics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. Jointly Announce NMPA Approval of Limertinib, a Third-Generation EGFR TKI for the Treatment of Lung Cancer Jan 19
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 28, 2025 Dec 31
Third quarter 2024 earnings released: EPS: CN¥0.062 (vs CN¥0.029 loss in 3Q 2023) Oct 31
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Sep 30
Second quarter 2024 earnings released: EPS: CN¥0.053 (vs CN¥0.10 loss in 2Q 2023) Aug 31
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Jun 29 See more updates Innovent Biologics, Inc. and Jiangsu Aosaikang Pharmaceutical Co. Ltd. Jointly Announce NMPA Approval of Limertinib, a Third-Generation EGFR TKI for the Treatment of Lung Cancer Jan 19
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 28, 2025 Dec 31
Third quarter 2024 earnings released: EPS: CN¥0.062 (vs CN¥0.029 loss in 3Q 2023) Oct 31
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Sep 30
Second quarter 2024 earnings released: EPS: CN¥0.053 (vs CN¥0.10 loss in 2Q 2023) Aug 31
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Jun 29
Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 29, 2024 Apr 30
First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.07 loss in 1Q 2023) Apr 29
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024 Mar 30
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 29, 2024 Dec 30
Third quarter 2023 earnings released: CN¥0.029 loss per share (vs CN¥0.19 loss in 3Q 2022) Nov 01
Second quarter 2023 earnings released: CN¥0.10 loss per share (vs CN¥0.004 loss in 2Q 2022) Aug 31
Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 26, 2023 May 06
Full year 2022 earnings released: CN¥0.24 loss per share (vs CN¥0.41 profit in FY 2021) Apr 29
Beijing Aosaikang Pharmaceutical Co., Ltd.(XSEC:002755) dropped from S&P Global BMI Index Dec 19
High number of new directors Dec 02
Third quarter 2022 earnings released: CN¥0.19 loss per share (vs CN¥0.14 profit in 3Q 2021) Oct 31
Investor sentiment improved over the past week Oct 19
Second quarter 2022 earnings released: CN¥0.004 loss per share (vs CN¥0.09 profit in 2Q 2021) Aug 29
Beijing Aosaikang Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2021, Payable on June 20, 2022 Jun 11
Beijing Aosaikang Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2021 May 24
Beijing Aosaikang Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021 May 08
Beijing Aosaikang Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022 May 07
First quarter 2022 earnings released: EPS: CN¥0.02 (vs CN¥0.19 in 1Q 2021) May 02
High number of new directors Mar 29
Beijing Aosaikang Pharmaceutical Co., Ltd. Announces Directorate Appointments Feb 22
Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.27 in 3Q 2020) Oct 31
Second quarter 2021 earnings released: EPS CN¥0.09 (vs CN¥0.14 in 2Q 2020) Aug 30
Beijing Aosaikang Pharmaceutical Co., Ltd. Approves 2020 Profit Distribution Plan May 21
Beijing Aosaikang Pharmaceutical Co., Ltd. Announces Cash Dividend for the Year 2020 Apr 29
First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.11 in 1Q 2020) Apr 29
Beijing Aosaikang Pharmaceutical Co., Ltd. (SZSE:002755) agreed to acquire 60% stake in Jiangsu Vedkang Medical Science and Technology Co., Ltd. from Changzhou Beiruishi Enterprise Management Co., Ltd., Changzhou Yisiyuan Enterprise Management Co., Ltd., Zhuang Xiaojin and Miao Donglin for approximately CNY 830 million. Apr 28
New 90-day low: CN¥12.69 Jan 07
New 90-day low: CN¥14.38 Dec 18
New 90-day low: CN¥15.75 Nov 24
Third quarter earnings released Oct 26
New 90-day low: CN¥15.78 Oct 23
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 26, 2020 Oct 19
New 90-day low: CN¥15.95 Sep 28
New 90-day low - CN¥17.32 Sep 09
First half earnings released Aug 31
Beijing Aosaikang Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020 Aug 10
New 90-day high - CN¥21.16 Aug 03 Shareholder Returns 002755 CN Pharmaceuticals CN Market 7D -0.8% -1.1% -0.6% 1Y 49.4% 0.5% 12.6%
See full shareholder returns
Return vs Market: 002755 exceeded the CN Market which returned 12.6% over the past year.
Price Volatility Is 002755's price volatile compared to industry and market? 002755 volatility 002755 Average Weekly Movement 6.3% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 6.9% 10% most volatile stocks in CN Market 10.9% 10% least volatile stocks in CN Market 4.1%
Stable Share Price: 002755 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002755's weekly volatility (6%) has been stable over the past year.
About the Company Beijing Aosaikang Pharmaceutical Co., Ltd. researches, develops, manufactures, markets, and sells pharmaceuticals, fine chemicals, and health-care products in China. It offers proton pump inhibitor injections and oncology medicines, as well as APIs. The company provides its products in digestive, oncology, antibiotic, and other areas.
Show more Beijing Aosaikang Pharmaceutical Co., Ltd. Fundamentals Summary How do Beijing Aosaikang Pharmaceutical's earnings and revenue compare to its market cap? 002755 fundamental statistics Market cap CN¥12.80b Earnings (TTM ) CN¥163.14m Revenue (TTM ) CN¥1.71b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 002755 income statement (TTM ) Revenue CN¥1.71b Cost of Revenue CN¥324.09m Gross Profit CN¥1.38b Other Expenses CN¥1.22b Earnings CN¥163.14m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 28, 2025
Earnings per share (EPS) 0.18 Gross Margin 81.03% Net Profit Margin 9.55% Debt/Equity Ratio 2.9%
How did 002755 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/28 00:18 End of Day Share Price 2025/01/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Beijing Aosaikang Pharmaceutical Co., Ltd. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Shitong Han Citic Securities Co., Ltd. Yinhao Tang Citic Securities Co., Ltd. Wei Zheng Tianfeng Securities Brokerage Co., Ltd
Show 0 more analysts